A carregar...
CFTR potentiators: From Bench to Bedside
One major breakthrough in cystic fibrosis research in the past decade is the development of drugs that target the root cause of the disease—dysfunctional CFTR protein. One of the compounds, Ivacaftor or Kalydeco, which has been approved for clinical use since 2012, acts by promoting the gating funct...
Na minha lista:
| Publicado no: | Curr Opin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5723237/ https://ncbi.nlm.nih.gov/pubmed/29073476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2017.09.015 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|